Technical Analysis for GTBP - GT Biopharma, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 3.75 | 2.78% | 0.10 |
Earnings due: May 13
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Outside Day | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Stochastic Buy Signal | Bullish | 2.78% | |
NR7 | Range Contraction | 2.78% | |
Narrow Range Bar | Range Contraction | 2.78% | |
Inside Day | Range Contraction | 2.78% | |
Oversold Stochastic | Weakness | 2.78% | |
New 52 Week Closing Low | Bearish | 2.78% | |
Doji - Bullish? | Reversal | 2.78% | |
Outside Day | Range Expansion | 2.78% |
Alert | Time |
---|---|
10 DMA Resistance | about 12 hours ago |
Rose Above Previous Day's High | about 16 hours ago |
Rose Above 10 DMA | about 16 hours ago |
Outside Day | about 16 hours ago |
Up 5% | about 16 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/13/2024
GT Biopharma, Inc. Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase 1 clinical trial; GTB-C3550, a next-generation follow-on to its lead candidates TriKE, GTB-3550, and GTB-C3550, which contains a modified CD16 moiety; and GTB-1615, a single-chain fusion protein for the treatment of solid tumors. Its central nervous system portfolio consists of GTP-004 for the treatment of myasthenia gravis, PainBrake to treat chronic neuropathic pain, and GTP-011 for the treatment of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is headquartered in Westlake Village, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Cancer Therapies Myasthenia Gravis Lectins Cd22 Siglec Treatment Of Myasthenia Gravis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.11 |
52 Week Low | 3.52 |
Average Volume | 13,428 |
200-Day Moving Average | 6.63 |
50-Day Moving Average | 4.20 |
20-Day Moving Average | 4.00 |
10-Day Moving Average | 3.77 |
Average True Range | 0.31 |
RSI (14) | 42.20 |
ADX | 11.32 |
+DI | 20.72 |
-DI | 20.77 |
Chandelier Exit (Long, 3 ATRs) | 3.87 |
Chandelier Exit (Short, 3 ATRs) | 4.47 |
Upper Bollinger Bands | 4.56 |
Lower Bollinger Band | 3.44 |
Percent B (%b) | 0.28 |
BandWidth | 27.91 |
MACD Line | -0.20 |
MACD Signal Line | -0.19 |
MACD Histogram | -0.0104 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.25 | ||||
Resistance 3 (R3) | 4.23 | 4.06 | 4.16 | ||
Resistance 2 (R2) | 4.06 | 3.93 | 4.06 | 4.14 | |
Resistance 1 (R1) | 3.90 | 3.85 | 3.98 | 3.92 | 4.11 |
Pivot Point | 3.73 | 3.73 | 3.77 | 3.73 | 3.73 |
Support 1 (S1) | 3.57 | 3.60 | 3.65 | 3.59 | 3.39 |
Support 2 (S2) | 3.40 | 3.52 | 3.40 | 3.37 | |
Support 3 (S3) | 3.24 | 3.40 | 3.34 | ||
Support 4 (S4) | 3.26 |